A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Astrazeneca AB

Enrolment target

802

Start

27 Mar 2023

Age 18 Years to any · Sex: All

• —

  Sweden
• —

  Romania
• —

  Spain
• —

  Italy
• —

  Germany
• —

  Poland
• —

  Finland
• —

  Czechia
• —

  Hungary
• —

  Bulgaria
• —

  Denmark
• —

  Belgium

+5 more sites — see the official record for the full list.